- Home
- GLUE vs ABSI Comparison
GLUE vs ABSI Comparison
Compare GLUE & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLUE
- ABSI
- Stock Information
- Founded
- GLUE 2019
- ABSI 2011
- Country
- GLUE United States
- ABSI United States
- Employees
- GLUE N/A
- ABSI N/A
- Industry
- GLUE Biotechnology: Pharmaceutical Preparations
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- GLUE Health Care
- ABSI Health Care
- Exchange
- GLUE Nasdaq
- ABSI Nasdaq
- Market Cap
- GLUE 283.6M
- ABSI 338.0M
- IPO Year
- GLUE 2021
- ABSI 2021
- Fundamental
- Price
- GLUE $5.20
- ABSI $2.67
- Analyst Decision
- GLUE Buy
- ABSI Strong Buy
- Analyst Count
- GLUE 2
- ABSI 4
- Target Price
- GLUE $13.50
- ABSI $8.75
- AVG Volume (30 Days)
- GLUE 415.2K
- ABSI 4.1M
- Earning Date
- GLUE 08-07-2025
- ABSI 08-13-2025
- Dividend Yield
- GLUE N/A
- ABSI N/A
- EPS Growth
- GLUE N/A
- ABSI N/A
- EPS
- GLUE 0.08
- ABSI N/A
- Revenue
- GLUE $159,487,000.00
- ABSI $4,815,000.00
- Revenue This Year
- GLUE $49.02
- ABSI $81.76
- Revenue Next Year
- GLUE N/A
- ABSI $287.79
- P/E Ratio
- GLUE $66.53
- ABSI N/A
- Revenue Growth
- GLUE 14889.38
- ABSI N/A
- 52 Week Low
- GLUE $3.50
- ABSI $2.01
- 52 Week High
- GLUE $12.40
- ABSI $6.33
- Technical
- Relative Strength Index (RSI)
- GLUE 64.63
- ABSI 46.51
- Support Level
- GLUE $4.42
- ABSI $2.54
- Resistance Level
- GLUE $4.85
- ABSI $2.92
- Average True Range (ATR)
- GLUE 0.24
- ABSI 0.15
- MACD
- GLUE 0.05
- ABSI 0.01
- Stochastic Oscillator
- GLUE 81.55
- ABSI 41.86
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.